Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Non Operating Income (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Non Operating Income for 12 consecutive years, with $65355.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income fell 47.2% year-over-year to $65355.0, compared with a TTM value of -$621020.0 through Sep 2025, down 177.56%, and an annual FY2024 reading of -$144474.0, down 121.42% over the prior year.
  • Non Operating Income was $65355.0 for Q3 2025 at Sunshine Biopharma, down from $74655.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $946747.0 in Q4 2021 and bottomed at -$4.9 million in Q1 2021.
  • Average Non Operating Income over 5 years is -$460483.2, with a median of $89141.0 recorded in 2024.
  • The sharpest move saw Non Operating Income crashed 8580.13% in 2021, then skyrocketed 1442.82% in 2023.
  • Year by year, Non Operating Income stood at $946747.0 in 2021, then tumbled by 91.06% to $84599.0 in 2022, then skyrocketed by 86.13% to $157464.0 in 2023, then tumbled by 631.45% to -$836848.0 in 2024, then surged by 107.81% to $65355.0 in 2025.
  • Business Quant data shows Non Operating Income for SBFM at $65355.0 in Q3 2025, $74655.0 in Q2 2025, and $75818.0 in Q1 2025.